Hangzhou Alltest Biotech Co. Ltd. A - Asset Resilience Ratio
Hangzhou Alltest Biotech Co. Ltd. A (688606) has an Asset Resilience Ratio of 11.88% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Hangzhou Alltest Biotech Co. Ltd. A carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Hangzhou Alltest Biotech Co. Ltd. A's Asset Resilience Ratio has changed over time. See Hangzhou Alltest Biotech Co. Ltd. A (688606) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Hangzhou Alltest Biotech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688606 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥488.18 Million | 11.88% |
| Total Liquid Assets | CN¥488.18 Million | 11.88% |
Asset Resilience Insights
- Moderate Liquidity: Hangzhou Alltest Biotech Co. Ltd. A has 11.88% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Hangzhou Alltest Biotech Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Hangzhou Alltest Biotech Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Innovative Eyewear Inc.
NASDAQ:LUCY |
Medical Instruments & Supplies | 0.00% |
|
QITIAN Technology Group Co Ltd
SHE:300061 |
Medical Instruments & Supplies | 0.00% |
|
Medeon Biodesign
TWO:6499 |
Medical Instruments & Supplies | 7.38% |
|
Ocumetics Technology Corp
V:OTC |
Medical Instruments & Supplies | 0.00% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
Annual Asset Resilience Ratio for Hangzhou Alltest Biotech Co. Ltd. A (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Hangzhou Alltest Biotech Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.23% | CN¥1.32 Billion ≈ $193.87 Million |
CN¥4.24 Billion ≈ $620.80 Million |
-8.36pp |
| 2024-12-31 | 39.59% | CN¥1.66 Billion ≈ $242.52 Million |
CN¥4.19 Billion ≈ $612.55 Million |
+3.85pp |
| 2023-12-31 | 35.75% | CN¥1.47 Billion ≈ $215.31 Million |
CN¥4.12 Billion ≈ $602.31 Million |
-3.25pp |
| 2022-12-31 | 39.00% | CN¥1.83 Billion ≈ $268.21 Million |
CN¥4.70 Billion ≈ $687.72 Million |
+19.54pp |
| 2021-12-31 | 19.46% | CN¥780.20 Million ≈ $114.17 Million |
CN¥4.01 Billion ≈ $586.55 Million |
-16.59pp |
| 2020-12-31 | 36.05% | CN¥415.00 Million ≈ $60.73 Million |
CN¥1.15 Billion ≈ $168.44 Million |
+17.41pp |
| 2019-12-31 | 18.65% | CN¥62.00 Million ≈ $9.07 Million |
CN¥332.50 Million ≈ $48.66 Million |
-- |
About Hangzhou Alltest Biotech Co. Ltd. A
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; flu… Read more